VALNEVA
Declaration of shares and voting rights
Status on December 31, 2022 (corrected data) and January 4, 2023
__________________________________________________________________________________________
Company name: VALNEVA
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)
Regulated market of Euronext Paris – Compartment A
Declaration date: January 19, 2023
Erratum: status on December 31, 2022
| Number of shares composing the share capital of Valneva |
Total number of voting rights including suspended voting rights* | Description of the change | Date on which this change was recognized | Total number of voting rights excluding suspended voting rights** |
|
138,367,482
including:
|
160,933,882 | Exercise of 12,500 BSA equity warrant
Double voting rights granted on 9,775 ordinary shares |
December 1st, 8 & 10, 2022
December 7, 9, 16 & 23, 2022 |
160,809,560 |
Interim status on January 4, 2023
| Number of shares composing the share capital of Valneva |
Total number of voting rights including suspended voting rights* | Description of the change | Date on which this change was recognized | Total number of voting rights excluding suspended voting rights** |
|
138,346,968 ordinary shares with a par value of €0.15 each |
160,933,882 | Cancellation of 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each | January 4, 2023 i | 160,809,560 |
i Management Board decisions of January 4, 2023.
___________________________
* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
** Net (or exercisable at a General Meeting) voting rights.
Attachment
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…